OCA
CBIO

Octagon Capital Advisors’s Crescent Biopharma CBIO Stock Holding History

Octagon Capital Advisors’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-30,000
Closed -$9M – 52
2024
Q1 		$9M Hold
30,000
– – 1.08% 26
2023
Q4 		$7.08M Hold
30,000
– – 1.13% 21
2023
Q3 		$4.5M Hold
30,000
– – 0.69% 28
2023
Q2 		$5.22M Hold
30,000
– – 0.73% 27
2023
Q1 		$3.78M Buy
+30,000
New +$6.75M 0.54% 28

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Octagon Capital Advisors's CBIO Position: Q2 2024 in Review

Octagon Capital Advisors sold out of Crescent Biopharma (CBIO) in Q2 2024, closing a stake of 30,000 shares — an estimated $9M sold.

Octagon Capital Advisors first reported a position in CBIO in Q1 2023 and held it in 5 quarters. The position peaked at $9M in Q1 2024. 35 funds tracked by Wall St. Rank hold CBIO as of Q2 2024.

  • Octagon Capital Advisors reported no remaining Crescent Biopharma position as of Q2 2024 after selling out during the quarter.
  • Octagon Capital Advisors sold 30,000 Crescent Biopharma shares in Q2 2024, an estimated $9M.
  • Octagon Capital Advisors first reported a position in Crescent Biopharma in Q1 2023 and held it in 5 quarters.
  • Octagon Capital Advisors's Crescent Biopharma position peaked at $9M in Q1 2024.
  • 35 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2024.

Based on Octagon Capital Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.